Cargando…
Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature
The tumor suppressor p53, encoded by the TP53 gene, is mutated or nullified in nearly 50% of human cancers. It has long been debated whether TP53 mutations can be utilized as a biomarker to predict clinical outcomes of cancer patients. In this study, we applied computational methods to calculate p53...
Autores principales: | Schaafsma, Evelien, Takacs, Eric M., Kaur, Sandeep, Cheng, Chao, Kurokawa, Manabu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789768/ https://www.ncbi.nlm.nih.gov/pubmed/35079034 http://dx.doi.org/10.1038/s41598-022-05243-6 |
Ejemplares similares
-
Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
por: Zhao, Yanding, et al.
Publicado: (2020) -
Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway
por: Bang, Scott, et al.
Publicado: (2019) -
A TMPRSS2‐ERG gene signature predicts prognosis of patients with prostate adenocarcinoma
por: Zhou, Emily, et al.
Publicado: (2020) -
Whole Transcriptome Signature for Prognostic Prediction (WTSPP): application of whole transcriptome signature for prognostic prediction in cancer
por: Schaafsma, Evelien, et al.
Publicado: (2020) -
Microglia-Based Gene Expression Signature Highly Associated with Prognosis in Low-Grade Glioma
por: Schaafsma, Evelien, et al.
Publicado: (2022)